Literature DB >> 15717652

Are subjects with erectile dysfunction aware of their condition? Results from a retrospective study based on an Italian free-call information service.

A Aversa1, A M Isidori, D Gianfrilli, E A Greco, A Graziottin, G Zizzo, A Lenzi, A Fabbri.   

Abstract

The aim of the study was to analyse the socio-demographic and epidemiological characteristics of the Italian male population affected by sexual disturbances. Men complaining of erectile dysfunction (ED) who called the Pfizer program "Man and Woman in Health" between April 18th 2001 and May 27th 2002 and asked for information about their medical condition, were interviewed by trained doctors using a computer-assisted questionnaire. 16007 out of 25018 calls were considered for statistical analysis. Mean age of callers was 48.8+/-14.2 yr, reporting ED in 83% of cases. In the majority of men ED was severe (58%) and lasting more than 3 yr (25%). Multivariate analysis revealed that diabetes, depression, prostate surgery, heart disease, neurological disorders, liver and renal diseases were all significant and independent contributors to the degree of erectile impairment adjusted for age (p<0.001). The principal concomitant medications were anti-hypertensive (23%), antidiabetic (9%) and cardiovascular agents (6%). Cigarette smoking was present in 24%. On directed questioning of the caller, anxiety and distress were perceived as the most frequent causes of ED (42%) across all age groups, followed by the presence of concomitant disease/s (26%) especially in aging men. Also, a large number of men (41 %) with severe ED waited for more than 3 yr before looking for medical referral. Interestingly, only 19% had ever tried any specific medication for ED. These data indicate that 5 yr after worldwide approval and release of sildenafil, ED is still largely undiagnosed and under-treated, possibly because it is still perceived as a condition mainly due to distress or advancing age and therefore not deserving medical referral. Effective prevention of ED commences with better awareness of the pathological causes by the population and modification of risk factors by the doctors.

Entities:  

Mesh:

Year:  2004        PMID: 15717652     DOI: 10.1007/BF03347477

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  19 in total

1.  Erectile dysfunction in hypertensive subjects. Assessment of potential determinants.

Authors:  A Jaffe; Y Chen; E S Kisch; B Fischel; M Alon; N Stern
Journal:  Hypertension       Date:  1996-11       Impact factor: 10.190

2.  Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'.

Authors:  M Braun; G Wassmer; T Klotz; B Reifenrath; M Mathers; U Engelmann
Journal:  Int J Impot Res       Date:  2000-12       Impact factor: 2.896

3.  Change in symptoms of hypertensive patients after referral to hospital clinic.

Authors:  C J Bulpitt; C T Dollery; S Carne
Journal:  Br Heart J       Date:  1976-02

4.  Hypertension and impotence.

Authors:  S C Müller; H el-Damanhoury; J Rüth; T F Lue
Journal:  Eur Urol       Date:  1991       Impact factor: 20.096

5.  Frequency and determinants of erectile dysfunction in Italy.

Authors:  F Parazzini; F Menchini Fabris; A Bortolotti; A Calabrò; L Chatenoud; E Colli; M Landoni; M Lavezzari; P Turchi; A Sessa; V Mirone
Journal:  Eur Urol       Date:  2000-01       Impact factor: 20.096

6.  Impotence in medical clinic outpatients.

Authors:  M F Slag; J E Morley; M K Elson; D L Trence; C J Nelson; A E Nelson; W B Kinlaw; H S Beyer; F Q Nuttall; R B Shafer
Journal:  JAMA       Date:  1983-04-01       Impact factor: 56.272

7.  Erectile dysfunction in diabetic subjects in Italy. Gruppo Italiano Studio Deficit Erettile nei Diabetici.

Authors:  D Fedele; C Coscelli; F Santeusanio; A Bortolotti; L Chatenoud; E Colli; M Landoni; F Parazzini
Journal:  Diabetes Care       Date:  1998-11       Impact factor: 19.112

8.  Cigarette smoking as risk factor for erectile dysfunction: results from an Italian epidemiological study.

Authors:  Vincenzo Mirone; Ciro Imbimbo; Angela Bortolotti; Elisabetta Di Cintio; Enrico Colli; Marina Landoni; Maurizio Lavezzari; Fabio Parazzini
Journal:  Eur Urol       Date:  2002-03       Impact factor: 20.096

9.  Current drug use as risk factor for erectile dysfunction: results from an Italian epidemiological study.

Authors:  E Ricci; F Parazzini; V Mirone; C Imbimbo; A Palmieri; A Bortolotti; E Di Cintio; M Landoni; M Lavezzari
Journal:  Int J Impot Res       Date:  2003-06       Impact factor: 2.896

Review 10.  Sexual dysfunction and depression: etiology, prevalence, and treatment.

Authors:  R Shabsigh; L Zakaria; A G Anastasiadis; A S Seidman
Journal:  Curr Urol Rep       Date:  2001-12       Impact factor: 2.862

View more
  5 in total

1.  Systemic and metabolic effects of PDE5-inhibitor drugs.

Authors:  Antonio Aversa
Journal:  World J Diabetes       Date:  2010-03-15

2.  Sex steroid metabolism in benign and malignant intact prostate biopsies: individual profiling of prostate intracrinology.

Authors:  Daniele Gianfrilli; Silvia Pierotti; Riccardo Pofi; Costantino Leonardo; Mauro Ciccariello; Federica Barbagallo
Journal:  Biomed Res Int       Date:  2014-08-13       Impact factor: 3.411

3.  EDEUS, a Real-Life Study on the Users of Phosphodiesterase Type 5 Inhibitors: Prevalence, Perceptions, and Health Care-Seeking Behavior Among European Men With a Focus on 2nd-Generation Avanafil.

Authors:  Giovanni Corona; Mario Maggi; Emmanuele A Jannini
Journal:  Sex Med       Date:  2017-12-21       Impact factor: 2.491

Review 4.  Needs and Expectations of Patients with Erectile Dysfunction: An Update on Pharmacological Innovations in Phosphodiesterase Type 5 Inhibition with Focus on Sildenafil.

Authors:  Emmanuele A Jannini; Stéphane Droupy
Journal:  Sex Med       Date:  2018-12-03       Impact factor: 2.491

5.  The SIAMS-ED Trial: A National, Independent, Multicentre Study on Cardiometabolic and Hormonal Impairment of Men with Erectile Dysfunction Treated with Vardenafil.

Authors:  Andrea M Isidori; Giovanni Corona; Antonio Aversa; Daniele Gianfrilli; Emmanuele A Jannini; Carlo Foresta; Mario Maggi; Andrea Lenzi
Journal:  Int J Endocrinol       Date:  2014-05-15       Impact factor: 3.257

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.